Trial reportThe British journal of psychiatry : the journal of mental science2016
Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre randomised controlled trial.
Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in The British journal of psychiatry : the journal of mental science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
65.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Utilizing computer vision for facial behavior analysis in schizophrenia studies: A systematic review.PloS one · 2022Pooled it
- Effectiveness of Body Psychotherapy. A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2021Pooled it
- Effects of Dance Movement Therapy and Dance on Health-Related Psychological Outcomes. A Meta-Analysis Update.Frontiers in psychology · 2019Pooled it
- A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation.Health technology assessment (Winchester, England) · 2024Trial
- BEATVIC, a body-oriented resilience therapy for individuals with psychosis: Short term results of a multi-center RCT.PloS one · 2022Trial
- Correspondence between negative symptoms and potential sources of secondary negative symptoms over time.European archives of psychiatry and clinical neuroscience · 2018Trial
- Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia.Patient related outcome measures · 2024Review
- Article
- Movement markers of schizophrenia: a detailed analysis of patients' gait patterns.European archives of psychiatry and clinical neuroscience · 2022Article
- Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.European archives of psychiatry and clinical neuroscience · 2022Article
- Splitting Things Apart to Put Them Back Together Again: A Targeted Review and Analysis of Psychological Therapy RCTs Addressing Recovery From Negative Symptoms.Frontiers in psychiatry · 2022Review
- EPA guidance on treatment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021Article
- Structure of Negative Symptoms in Schizophrenia: An Unresolved Issue.Frontiers in psychiatry · 2021Article
- Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis.Psychosis · 2021Article
- Efficacy of Psychological Treatments for Patients With Schizophrenia and Relevant Negative Symptoms: A Meta-Analysis.Clinical psychology in Europe · 2020Review
- Article
- Article
- Do adjunctive art therapies reduce symptomatology in schizophrenia? A meta-analysis.World journal of psychiatry · 2019Article
- Preferences for befriending schemes: a survey of patients with severe mental illness.BMC psychiatry · 2018Article
- Efficacy Towards Negative Symptoms and Safety of Repetitive Transcranial Magnetic Stimulation Treatment for Patients with Schizophrenia: A Systematic Review.Shanghai archives of psychiatry · 2017Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 2 countries.
S PriebeS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK s.priebe@qmul.ac.uk.
M SavillS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
T WykesS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
R P BentallS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
U ReininghausS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
C LauberS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
S BremnerS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
S EldridgeS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
F RöhrichtS. Priebe, FRCPsych, M. Savill, PhD, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK; T. Wykes, PhD, Institute of Psychiatry, Kings College London, London, UK; R. P. Bentall, PhD, Department of Psychiatry, University of Liverpool, Liverpool, UK; U. Reininghaus, MSc, DiplPsych, Institute of Psychiatry, Kings College London, London, UK and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University, The Netherlands; C. Lauber, MD, Services Psychiatriques, Jura Bernois - Bienne-Seeland, Bellelay, Switzerland; S. Bremner, PhD, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; S. Eldridge, MSc, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK; F. Röhricht, MD, MRCPsych, Unit for Social and Community Psychiatry, WHO Collaborative Centre for Mental Health Services Development, Queen Mary University of London, London, UK.
Queen Mary University of London · GBCentre for Mental Health · GBUniversity of Liverpool · GBUniversity of Sussex · GB
Funding
Department of Health 08/116/68
Abstract
backgroundNegative symptoms of schizophrenia have a severe impact on functional outcomes and treatment options are limited. Arts therapies are currently recommended but more evidence is required.
aimsTo assess body psychotherapy as a treatment for negative symptoms compared with an active control (trial registration: ISRCTN84216587).
methodSchizophrenia out-patients were randomised into a 20-session body psychotherapy or Pilates group. The primary outcome was negative symptoms at end of treatment. Secondary outcomes included psychopathology, functional, social and treatment satisfaction outcomes at treatment end and 6-months later.
resultsIn total, 275 participants were randomised. The adjusted difference in negative symptoms was 0.03 (95% CI -1.11 to 1.17), indicating no benefit from body psychotherapy. Small improvements in expressive deficits and movement disorder symptoms were detected in favour of body psychotherapy. No other outcomes were significantly different.
conclusionsBody psychotherapy does not have a clinically relevant beneficial effect in the treatment of patients with negative symptoms of schizophrenia.
Indexed as
Outcome Assessment, Health CareAdultExercise Movement TechniquesFemaleFollow-Up StudiesHumansMaleMiddle AgedPsychotherapy, GroupSchizophrenia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.